0.335
전일 마감가:
$0.4316
열려 있는:
$0.3402
하루 거래량:
7.04M
Relative Volume:
2.02
시가총액:
$2.85M
수익:
-
순이익/손실:
$-22.71M
주가수익비율:
-0.0286
EPS:
-11.71
순현금흐름:
$-18.24M
1주 성능:
+23.57%
1개월 성능:
+0.00%
6개월 성능:
-4.45%
1년 성능:
-88.80%
Genprex Inc Stock (GNPX) Company Profile
명칭
Genprex Inc
전화
512-537-7997
주소
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
GNPX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
GNPX
Genprex Inc
|
0.335 | 2.85M | 0 | -22.71M | -18.24M | -11.71 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2021-01-26 | 개시 | National Securities | Buy |
2019-04-29 | 개시 | Noble Capital Markets | Outperform |
Genprex Inc 주식(GNPX)의 최신 뉴스
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Genprex Delays Yearly Report Filing - TipRanks
Genprex Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Genprex, Inc. SEC 10-K Report - TradingView
Genprex (GNPX) Projected to Announce Earnings on Monday - Defense World
Genprex stock plunges to 52-week low of $0.27 By Investing.com - Investing.com South Africa
Genprex stock plunges to 52-week low of $0.27 - Investing.com India
Genprex reports progress in lung cancer gene therapy By Investing.com - Investing.com South Africa
Genprex reports progress in lung cancer gene therapy - Investing.com India
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting - PR Newswire
Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions - Quantisnow
Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® De - GuruFocus.com
Genprex Inc (GNPX) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
Genprex to Participate at BIO Europe Spring 2025 - StreetInsider.com
Can Genprex's Presence at BIO Europe Spring Attract New Partnership Opportunities? - Stock Titan
Genprex to Present at the 2020 LD Micro Virtual Conference - ACCESS Newswire
Genprex Strengthens Diabetes Focus with New License - TipRanks
Genprex explores non-viral gene therapy for diabetes By Investing.com - Investing.com Nigeria
Genprex Advances Diabetes Program With Addition Of Research Focused On Non-Viral Delivery System - Marketscreener.com
Genprex explores non-viral gene therapy for diabetes - Investing.com India
Can This New Delivery System Transform Diabetes Gene Therapy? Genprex's Latest Breakthrough - StockTitan
Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System - Seeking Alpha
Genprex advances diabetes gene therapy with new license By Investing.com - Investing.com Nigeria
Genprex Provides Update On Diabetes Gene Therapy Program -February 18, 2025 at 10:03 am EST - Marketscreener.com
Genprex announces advancement of its diabetes gene therapy program - TipRanks
Genprex advances diabetes gene therapy with new license - Investing.com India
Genprex Provides Update on Diabetes Gene Therapy Program - Nasdaq
Genprex faces Nasdaq delisting over stock price, equity issues - MSN
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer - BioSpace
Genprex's New Study Highlights NPRL2 Gene Therapy's Antitumor Activity In Lung Cancer - Nasdaq
Understanding GNPX’s financial ratios: A beginner’s guide - US Post News
Genprex faces Nasdaq delisting over stock price, equity issues By Investing.com - Investing.com Canada
Contrasting Genprex (NASDAQ:GNPX) & Avadel Pharmaceuticals (NASDAQ:AVDL) - Defense World
GNPX’s Market Whiplash: -38.94% YTD Decline, -42.28% Plunge in 30 Days - The InvestChronicle
Genprex Inc (NASDAQ: GNPX): An Enticing Stock To Watch - Stocks Register
Genprex doses first subject in expansion part of lung cancer gene therapy trial - Clinical Trials Arena
Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer - PR Newswire
Genprex, Inc. (NASDAQ: GNPX) Provides Updates on Oncology and Diabetes Programs - Defense World
Genprex Advances Cancer Trials and Diabetes Therapy - Yahoo Finance
Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
Genprex Inc (GNPX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):